Vertex Solutions, a small business known for the manufacturing of systems integration and advanced training technologies, has ...

In a series of recent legal challenges initiated by the pharmaceutical industry against the US Department of Health and Human Services Office of ...

Morgan Stanley lowered the firm’s price target on Vertex (VERX) to $55 from $60 and keeps an Overweight rating on the shares. The firm is ...

In a report released today, Chris Quintero from Morgan Stanley maintained a Buy rating on Vertex (VERX – Research Report), with a price target ...

Vertex Pharmaceuticals made headlines with a 14% share price jump, despite an overall market dip, thanks to clinical wins and ...

derives from Vertex’ near $1 billion acquisition of Semma in 2019, and has started enrolling patients in a phase 1/2 study in the US. The therapy takes the form of stem cell-derived human ...

If you see inaccuracies in our content, please report the mistake via this form. ZDNET's reviewers spend weeks to months testing each product or service on this list, using them for both everyday ...

I can get over the weight for that. Form-Factored -Typing is a pain with the phone shape and the way the weight is distributed. It's also a little big to fit into your pocket, I recommend a ...

Vertex Pharmaceuticals’ short interest has dropped by 22.32%, now sitting at 1.74% of its float—Wall Street seems less pessimistic. Short interest reflects how many shares are being bet against and ...